U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...

U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase 3 Trial in 2H 2025 – ...

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...